Which method of determining MGMT promoter methylation best predicts survival in people with glioblastoma treated with temozolomide?

In March 2021, the Cochrane Neuro-Oncology Group published a series of eight new systematic reviews on priority topics for the brain tumour community. These were selected from the most important unanswered questions identified by patients, the public and practitioners. In this podcast, Kathreena Kurian from the University of Bristol in the UK tells us about one of the reviews, which looked at the evidence on tests that might help to predict survival in patients who have received chemotherapy for glioblastoma.
Source: Podcasts from The Cochrane Library - Category: General Medicine Authors: Source Type: podcasts